SCHEMBL15037201

SCHEMBL15037201

CCCOc1ccc(-c2cnc(-c3ccc(C[C@H](NC(=O)c4ccc(C(C)(C)C)cc4)C(=O)O)cc3)nc2)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ITGB3 P05106 5/20 0.49
▸ ITGA2B P08514 4/20 0.49
▸ GPR132 Q9UNW8 1/20 0.48
▸ ITGB1 P05556 4/20 0.47
▸ ITGAV P06756 1/20 0.47
▸ ITGA5 P08648 1/20 0.47
▸ ITGA4 P13612 3/20 0.47
▸ TAS1R3 Q7RTX0 1/20 0.45
▸ TAS1R1 Q7RTX1 1/20 0.45
▸ L3MBTL1 Q9Y468 1/20 0.45
▸ KDM4E B2RXH2 1/20 0.45
▸ KDM4A O75164 1/20 0.45
▸ CA2 P00918 1/20 0.45
▸ GAA P10253 1/20 0.45
▸ RAB9A P51151 1/20 0.45
▸ KLKB1 P03952 1/20 0.44
▸ PPARG P37231 2/20 0.43
▸ PPARA Q07869 1/20 0.43
▸ EPHX2 P34913 1/20 0.43
▸ NR1H4 Q96RI1 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15037202 0.96 ITGB3 (0.52) ITGB3ITGA2BGPR132ITGB1ITGAV
SCHEMBL15037204 0.95 ITGB1 (0.55) ITGB3ITGA2BGPR132ITGB1ITGAV
SCHEMBL15037061 0.94 ITGB3 (0.54) ITGB3ITGA2BGPR132ITGB1ITGAV
SCHEMBL15037062 0.94 ITGB3 (0.54) ITGB3ITGA2BGPR132ITGB1ITGAV
SCHEMBL15092133 0.94 ITGB3 (0.54) ITGB3ITGA2BGPR132ITGB1ITGAV
SCHEMBL15019521 0.94 ITGB3 (0.54) ITGB3ITGA2BGPR132ITGB1ITGAV
SCHEMBL15019519 0.94 ITGB3 (0.54) ITGB3ITGA2BGPR132ITGB1ITGAV
SCHEMBL15037069 0.94 ITGB3 (0.54) ITGB3ITGA2BGPR132ITGB1ITGAV
SCHEMBL22449180 0.94 ITGB3 (0.54) ITGB3ITGA2BGPR132ITGB1ITGAV
SCHEMBL22449209 0.93 GAA (0.53) ITGB3ITGA2BGPR132ITGB1ITGAV

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3008056-B1 NOVEL GLP-1 RECEPTOR MODULATORS CELGENE INT II SARL (CH) 2020-12-09 — — EP disclosed
EP-2791112-B1 CARBOXYLIC ACID DERIVATIVES COMPRISING FOUR CYCLES ACTING AS GLP-1 RECEPTOR MODULATORS FOR THERAPY OF DISEASES SUCH AS DIABETES CELGENE INT II SÀRL (CH) 2020-09-23 — — EP disclosed
EP-3230276-B1 GLP-1 RECEPTOR MODULATORS CELGENE INT II SARL (CH) 2020-09-02 — — EP disclosed
US-10259823-B2 GLP-1 receptor modulators CELGENE INTERNATIONAL II SÀRL (CH) 2019-04-16 — — US disclosed
US-10034886-B2 GLP-1 receptor modulators CELGENE INTERNATIONAL II SÀRL (CH) 2018-07-31 — — US disclosed
US-20180021346-A1 NOVEL GLP-1 RECEPTOR MODULATORS RECEPTOS LLC 2018-01-25 — — US disclosed
US-20170313717-A1 NOVEL GLP-1 RECEPTOR MODULATORS RECEPTOS LLC 2017-11-02 — — US disclosed
US-9795613-B2 GLP-1 receptor modulators CELGENE INTERNATIONAL II SÀRL (CH) 2017-10-24 — — US disclosed
US-20160228450-A1 NOVEL GLP-1 RECEPTOR MODULATORS RECEPTOS LLC 2016-08-11 — — US disclosed
US-20160214993-A1 NOVEL GLP-1 RECEPTOR MODULATORS RECEPTOS LLC 2016-07-28 — — US disclosed
US-9187522-B2 GLP-1 receptor modulators RECEPTOS, INC. (US) 2015-11-17 — — US disclosed
US-20150038416-A1 NOVEL GLP-1 RECEPTOR MODULATORS RECEPTOS LLC 2015-02-05 — — US disclosed
US-20150011527-A1 NOVEL GLP-1 RECEPTOR MODULATORS RECEPTOS LLC 2015-01-08 — — US disclosed
US-8778923-B2 GLP-1 receptor modulators RECEPTOS, INC. (US) 2014-07-15 — — US disclosed
US-20130178420-A1 NOVEL GLP-1 RECEPTOR MODULATORS RECEPTOS, INC. (US) 2013-07-11 — — US disclosed
WO-2013090454-A2 NOVEL GLP-1 RECEPTOR MODULATORS RECEPTOS, INC. (US) 2013-06-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160228450-A1 NOVEL GLP-1 RECEPTOR MODULATORS GLP1R, GIPR, NPY1R ITGB3 4025/4885ITGA2B 4142/4885GPR132 178/4885
US-20170313717-A1 NOVEL GLP-1 RECEPTOR MODULATORS GLP1R, GIPR, NPY1R ITGB3 4025/4885ITGA2B 4142/4885GPR132 178/4885
US-20160214993-A1 NOVEL GLP-1 RECEPTOR MODULATORS GLP1R, GIPR, NPY1R ITGB3 4025/4885ITGA2B 4142/4885GPR132 178/4885
US-20180021346-A1 NOVEL GLP-1 RECEPTOR MODULATORS GLP1R, GIPR, NPY1R ITGB3 4025/4885ITGA2B 4142/4885GPR132 178/4885
US-20130178420-A1 NOVEL GLP-1 RECEPTOR MODULATORS GLP1R, GIPR, NPY1R ITGB3 4076/4885ITGA2B 4325/4885GPR132 156/4885
US-20150038416-A1 NOVEL GLP-1 RECEPTOR MODULATORS GLP1R, GIPR, NPY1R ITGB3 4076/4885ITGA2B 4325/4885GPR132 156/4885
US-10034886-B2 GLP-1 receptor modulators GLP1R, GIPR, GCGR ITGB3 3678/4885ITGA2B 4134/4885GPR132 228/4885
US-10259823-B2 GLP-1 receptor modulators GLP1R, GIPR, GCGR ITGB3 3678/4885ITGA2B 4134/4885GPR132 228/4885
US-20150011527-A1 NOVEL GLP-1 RECEPTOR MODULATORS GLP1R, GIPR, NPY1R ITGB3 4025/4885ITGA2B 4142/4885GPR132 178/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback